Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and/or congestive heart failure
Abstract
Novel use of an inhibitor of the renin-angiotensin system or derivative (I) in the manufacture of a medicament for the prevention of stroke in patients exhibiting normal or low blood pressure, diabetes and/ or congestive heart failure (CHF) with no pre-existing CHF. Independent claims are also included for: a method of preventing of stroke in patients exhibiting normal or low blood pressure, diabetes and/ or congestive heart failure (CHF) with no pre-existing CHF; and a formulation for use in the prevention of stroke in patients exhibiting normal or low blood pressure, diabetes and/ or congestive heart failure (CHF) with no pre-existing CHF. ACTIVITY : Cerebroprotective; Cardiant; Antidiabetic. Treating 9,541 patients who are at risk for cardiovascular events due to a history of previous ischemic heart disease, stroke, peripheral arterial disease or individuals with diabetes with ramipril for 6 years resulted in a 32% reduction in the number of patients who developed a stroke, 21% who developed congestive heart failure, and 36% reduction who developed diabetes. MECHANISM OF ACTION : Angiotensin converting enzyme (ACE) inhibitor; an angiotensin II antagonist.
Term
Term ended
Projected expiry passed 25 August 2020, 6.1 years ago.
- Priority
- Filed
- Published
- Projected expiry
- Today
94 members in 36 offices
Priority claims8
| Document | Office | Kind | Date |
|---|---|---|---|
| 9903028 | Sweden | A | |
| 9903028 | Sweden | A | |
| 0008341 | European Patent Office (EPO) | W | |
| 0008341 | European Patent Office (EPO) | W | |
| 00EP0008341 | – | – | – |
| 999903028 | – | – | – |
| SE19990003028 | – | – | – |
| WO2000EP08341 | – | – | – |
Members94
| Document | Office | Kind | |
|---|---|---|---|
| SE9903028D0 | Sweden | D0 | |
| CA2382387A1 | Canada | A1 | |
| WO0115673A2 | World Intellectual Property Organization (WIPO) | A2 | |
| AU7648400A | Australia | A | |
| NO20020850D0 | Norway | D0 | |
| NO20020850L | Norway | L | |
| NO20100569L | Norway | L | |
| WO0115673A3 | World Intellectual Property Organization (WIPO) | A3 | |
| BR0013540A | Brazil | A | |
| CZ2002644A3 | Czechia | A3 | |
| EP1212081A2 | European Patent Office (EPO) | A2 | |
| TR200200518T2 | Türkiye | T2 | |
| KR20020060167A | Republic of Korea | A | |
| MXPA02001633A | Mexico | A | |
| SK2702002A3 | Slovakia | A3 | |
| IL148126D0 | Israel | D0 | |
| CN1384756A | China | A | |
| TR200202466T2 | Türkiye | T2 | |
| TR200202467T2 | Türkiye | T2 | |
| HU0202461A2 | Hungary | A2 | |
| BG106319A | Bulgaria | A | |
| TR200202463T2 | Türkiye | T2 | |
| TR200202464T2 | Türkiye | T2 | |
| JP2003508426A | Japan | A | |
| EE200200085A | Estonia | A | |
| HU0202461A3 | Hungary | A3 | |
| ZA200201471B | South Africa | B | |
| HK1050327A1 | Hong Kong, China | A1 | |
| PL353066A1This record | Poland | A1 | |
| RU2002107673A | Russian Federation | A | |
| EP1437131A1 | European Patent Office (EPO) | A1 | |
| YU3602A | Yugoslavia, later Serbia and Montenegro (until 2006) | A | |
| CA2382387C | Canada | C | |
| AU2005203694A1 | Australia | A1 | |
| EP1212081B1 | European Patent Office (EPO) | B1 | |
| HRP20020169A2 | Croatia | A2 | |
| AT307604T | Austria | T | |
| DE60023518D1 | Germany | D1 | |
| EP1212081B8 | European Patent Office (EPO) | B8 | |
| DK1212081T3 | Denmark | T3 | |
| RU2272651C2 | Russian Federation | C2 | |
| ES2250192T3 | Spain | T3 | |
| SI1212081T1 | Slovenia | T1 | |
| DE60023518T2 | Germany | T2 | |
| US2006194868A1 | United States of America | A1 | |
| UA76702C2 | Ukraine | C2 | |
| RU2005128124A | Russian Federation | A | |
| KR20080035703A | Republic of Korea | A | |
| EP1925303A2 | European Patent Office (EPO) | A2 | |
| US2008125472A1 | United States of America | A1 | |
| CN100408093C | China | C | |
| EE05130B1 | Estonia | B1 | |
| AU2009200551A1 | Australia | A1 | |
| CN101537181A | China | A | |
| UA88270C2 | Ukraine | C2 | |
| US2009258919A1 | United States of America | A1 | |
| RU2378018C2 | Russian Federation | C2 | |
| BG110479A | Bulgaria | A | |
| NZ571901A | New Zealand | A | |
| NO329245B1 | Norway | B1 | |
| AU2009200551B2 | Australia | B2 | |
| ME00181B | Montenegro | B | |
| MEP28208A | Montenegro | A | |
| US2010267798A1 | United States of America | A1 | |
| EP1925303A3 | European Patent Office (EPO) | A3 | |
| EP2277519A2 | European Patent Office (EPO) | A2 | |
| BG66115B1 | Bulgaria | B1 | |
| EP2277519A3 | European Patent Office (EPO) | A3 | |
| US2011263619A1 | United States of America | A1 | |
| JP4843172B2 | Japan | B2 | |
| EP1437131B1 | European Patent Office (EPO) | B1 | |
| AT554761T | Austria | T | |
| PT1437131E | Portugal | E | |
| DK1437131T3 | Denmark | T3 | |
| ES2386141T3 | Spain | T3 | |
| CZ303433B6 | Czechia | B6 | |
| SI1437131T1 | Slovenia | T1 | |
| HU229107B1 | Hungary | B1 | |
| US2013317047A1 | United States of America | A1 | |
| RS52907B | Serbia | B | |
| EP1212081B2 | European Patent Office (EPO) | B2 | |
| ES2250192T5 | Spain | T5 | |
| DK1212081T4 | Denmark | T4 | |
| DE60023518T3 | Germany | T3 | |
| SI1212081T2 | Slovenia | T2 | |
| EP1925303B1 | European Patent Office (EPO) | B1 | |
| PT1925303E | Portugal | E | |
| ES2525699T3 | Spain | T3 | |
| IL148126A | Israel | A | |
| DK1925303T3 | Denmark | T3 | |
| SI1925303T1 | Slovenia | T1 | |
| SK288239B6 | Slovakia | B6 | |
| CY1112987T1 | Cyprus | T1 | |
| CY1115869T1 | Cyprus | T1 |
3 legal events, as the office reported them to INPADOC
Over the term
Point at a mark for the eventEvents
| Event | Code | |
|---|---|---|
| Invalidation of derivated patent or utility modelVDSO | VDSO | |
| Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)REFS | REFS | |
| Invalidation of derivated patent or utility modelVDSO | VDSO |
Numbers
- Publication, DOCDB
- 353066
- Publication, EPODOC
- PL353066
- Application
- 353066
- Application, DOCDB
- 35306600
- Application, EPODOC
- PL20000353066
Titles2
- English
- PHARMACEUTICAL FORMULATIONS AND USE THEREOF IN THE PREVENTION OF STROKE, DIABETES AND/OR CONGESTIVE HEART FAILURE
- Polish
- Preparaty farmaceutyczne i ich zastosowanie w profilaktyce udaru, cukrzycy i/lub zastoinowej niewydolności krążenia
Classification
- CPC, 18
- A61K31/403
- A61K31/40
- A61K31/519
- A61P25/28
- A61P3/00
- A61P3/10
- A61P43/00
- A61P7/12
- A61P9/00
- A61P9/02
- A61P9/04
- A61P9/08
- A61P9/10
- A61P9/12
- A61P9/14
- A61K31/41
- A61K31/4178
- A61K31/4184
- IPC, 23
- A61K31 00
- A61K31 357
- A61K31 401
- A61K31 4025
- A61K31 403
- A61K31 404
- A61K45 00
- A61K31 41
- A61K31 4166
- A61K31 4178
- A61K31 4184
- A61K31 435
- A61K31 497
- A61K31 519
- A61K31 55
- A61K31 551
- A61K31 554
- A61P3 10
- A61P9 02
- A61P9 04
- A61P9 10
- A61P43 00
- C07D209 52